uniQure N.V. Goodwill & Intangibles Disclosure
9. Intangible assets, net and Goodwill
The following table presents the Company’s acquired licenses, intangible asset related to the favorable supply terms under the CSA and Acquired IPR&D Intangible Asset as of December 31, 2025 and 2024, respectively:
December 31, 2025 | |||||||||
| Gross Carrying Amount | | Accumulated Amortization | | Net | ||||
(in thousands) | |||||||||
Acquired licenses | $ | 2,576 | $ | (1,402) | $ | 1,174 | |||
Favorable supply terms under CSA | 16,700 | (8,021) | 8,679 | ||||||
Total amortizable intangible assets | 19,276 | (9,423) | 9,853 | ||||||
Acquired IPR&D Intangible Asset | 62,937 | — | 62,937 | ||||||
Total intangible assets | $ | 82,213 | $ | (9,423) | $ | 72,790 | |||
December 31, 2024 | |||||||||
| Gross Carrying Amount | | Accumulated Amortization | | Net | ||||
(in thousands) | |||||||||
Acquired licenses | $ | 2,276 | $ | (1,117) | $ | 1,159 | |||
Favorable supply terms under CSA | 16,700 | (2,454) | 14,246 | ||||||
Total amortizable intangible assets | 18,976 | (3,571) | 15,405 | ||||||
Acquired IPR&D Intangible Asset | 55,638 | — | 55,638 | ||||||
Total intangible assets | $ | 74,614 | $ | (3,571) | $ | 71,043 | |||
As of December 31, 2025, the estimated future amortization expense for each of the five succeeding years and the period thereafter is as follows:
Years | | Amount | |
(in thousands) | |||
2026 | $ | 5,705 | |
2027 |
| 3,250 | |
2028 |
| 138 | |
2029 |
| 138 | |
2030 |
| 138 | |
Thereafter |
| 484 | |
Total | $ | 9,853 | |
| a. | Acquired licenses |
All acquired licenses are owned by uniQure biopharma. The remaining weighted average life is 8.5 years as of December 31, 2025 (December 31, 2024: 9.5 years).
The amortization expense related to acquired licenses for the year ended December 31, 2025 was $0.1 million (December 31, 2024: $0.1 million and December 31, 2023: $0.1 million).
| b. | Favorable supply terms under the CSA |
As part of the Lexington Transaction, the Company recognized an intangible asset related to its rights to purchase HEMGENIX at terms considered favorable to market terms. Refer to Note 3 “Divestment of commercial manufacturing activities”. The intangible asset is amortized on a straight line basis over a three-year period that commenced in July 2024.
The amortization expense related to the intangible asset for the year ended December 31, 2025 was $5.6 million (December 31, 2024: $2.5 million and December 31, 2023: nil).
| c. | Acquired in-process research and development |
The IPR&D Intangible Asset was recorded as part of the uniQure France Acquisition. Refer to Note 2.3.12 “Goodwill and acquired research and development intangible asset”.
| d. | Goodwill |
The goodwill was recorded as part of the uniQure France Acquisition. Refer to Note 2.3.12 “Goodwill and acquired research and development intangible asset”.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 2, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Feb 28, 2024 | |
| 2022 | Feb 27, 2023 | |
| 2021 | Feb 25, 2022 | |
| 2020 | Mar 1, 2021 | |
| 2019 | Mar 2, 2020 | |
| 2018 | Feb 28, 2019 | |
| 2017 | Mar 14, 2018 | |
| 2016 | Mar 15, 2017 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.